Prevents itching associated with allergic conjunctivitis. NDA 22134, held by Abbvie. Alcaftadine.
As of Nov 15, 2026, NDA 22134 (Lastacaft), held by Abbvie, was first approved by FDA on Jul 28, 2010, with 7 approved supplements and 0 published complete response letters.
LASTACAFT is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
| Dec 10, 2021 | Supplement 8Efficacy (new indication or use) · Standard review | Approved | |
| Jul 28, 2010 | Original applicationNew molecular entity · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lastacaft0.25% · solution/drops;ophthalmic | Alcaftadine | OTCReference drug |
| Aug 29, 2022 | Supplement 9Labeling · Standard review | Approved | |
| Dec 10, 2021 | Supplement 8Efficacy (new indication or use) · Standard review | Approved | |
| Jun 9, 2020 | Supplement 7Labeling · Standard review | Approved | |
| Sep 30, 2015 | Supplement 4Labeling · Standard review | Approved | |
| Dec 4, 2014 | Supplement 1Labeling · Standard review | Approved | |
| Aug 12, 2014 | Supplement 2Manufacturing · Standard review | Approved | None posted |
| Jul 25, 2014 | Supplement 3Manufacturing · Standard review | Approved | None posted |
| Jul 28, 2010 | Original applicationNew molecular entity · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
